1 Profiling pre-symptomatic and asymptomatic cases with confirmed SARS-CoV-2

- 2 infection in Mexico City
- 3 Omar Yaxmehen Bello-Chavolla MD, PhD1*, Neftali Eduardo Antonio-Villa MD2, Arsenio
- 4 Vargas-Vázquez², Carlos A. Fermín-Martínez², Alejandro Márquez-Salinas², Jessica Paola
- 5 Bahena-López MD²

6

9

- ¹Division of Research, Instituto Nacional de Geriatría. ²MD/PhD (PECEM), Faculty of Medicine,
- 8 National Autonomous University of Mexico.
- 10 Short title: Asymptomatic SARS-CoV-2 in Mexico City
- 12 Corresponding author
- 13 Omar Yaxmehen Bello-Chavolla. Division of Research. Instituto Nacional Geriatría. Anillo Perif.
- 2767, San Jerónimo Lídice, La Magdalena Contreras, 10200, Mexico City, Mexico. Phone: +52
- 15 (55) 5548486885. E-mail: oyaxbell@yahoo.com.mx
- 16 **CONFLICT OF INTERESTS:** Nothing to disclose.
- 17 **FUNDING:** This research received no specific funding
- Word count: 1,322 words; 2 Figures, 1 Table.

ABSTRACT (250 WORDS)

19

44

sources 20 **BACKGROUND:** Asymptomatic SARS-CoV-2 infections are potential 21 transmission. 22 OBJECTIVES: Here, we aimed to profile pre-symptomatic/asymptomatic SARS-CoV-2 infections in Mexico City, its associated comorbidities and outcomes. 23 METHODS: Prospective observational study of SARS-CoV-2 cases assessed by contact 24 25 tracing within the National Epidemiological Surveillance System in Mexico City. We classified 26 subjects as cases with and without respiratory and non-respiratory symptoms (RS, NRS, 27 respectively) assessed for SARS-CoV-2 using real time RT-PCR from nasopharyngeal swabs to evaluate clinical characteristics as well as features associated with severe COVID-19. 28 29 **RESULTS:** Amongst 80735 cases with confirmed SARS-CoV-2 infection as of July 23th, 2020, we identified 9659 cases without RS (12.0%), 5605 had only NRS (6.9%) and 4054 who were 30 31 initially asymptomatic (5.1%). Compared to asymptomatic cases, NRS cases and those with 32 RS+NRS had higher rates of severe COVID-19 outcomes including hospitalization, ICU admission, and intubation (p<0.001). Mortality was higher for cases with RS+NRS (HR 7.58, 33 34 95%CI 4.56-12.58) or NRS (HR 3.13, 95%CI 1.80-5.45) compared to asymptomatic cases, adjusted for age, sex and comorbidities. Predictors for mortality in asymptomatic SARS-Co-V-35 2 infections, chronic kidney disease, previous exposure with suspected infection cases and 36 older age were predictors for lethality. 37 38 **CONCLUSIONS:** Definition of pre-symptomatic/asymptomatic cases has relevant implications 39 for SARS-CoV-2 infection outcomes. Older age and comorbidity impact on the probability of 40 developing severe complications for cases who were asymptomatic or had only NRS at evaluation and were sent for domiciliary treatment. Extending testing for detection of 41 42 asymptomatic cases must be considered in Mexico to better understand the impact of the 43 pandemic.

Keywords: SARS-CoV-2; Asymptomatic; Pre-symptomatic; Mexico; COVID-19 outcomes

INTRODUCTION

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

Asymptomatic infections are a potential source of rapid SARS-CoV-2 spread [1]. Prevalence of pre-symptomatic/asymptomatic cases varies widely but represent a larger proportion of cases than previously anticipated [2]. Controversies surrounding asymptomatic SARS-CoV-2 infections have focused on the distinction between pre-symptomatic and asymptomatic infection and its definitions, which have focused on respiratory symptoms (RS), primarily cough, dyspnea and fever. Nevertheless, longitudinal data shows that only a fraction of initially asymptomatic infections develop subsequent symptoms [3–5]. In Mexico, SARS-CoV-2 testing focuses on sampling high-risk cases, which allowed characterization of increased susceptibility for severe COVID-19 attributable to cardio-metabolic comorbidities [6]; however, no data has been reported on asymptomatic SARS-CoV-2 infections. Lack of information regarding presymptomatic/asymptomatic cases in Mexico is concerning, particularly since many studies suggest that contact tracing of asymptomatic infections will be pivotal to contain further SARS-CoV-2 spread [7]. Here, we profile pre-symptomatic/asymptomatic cases of SARS-CoV-2 infections to assess outcomes depending on its definitions using cases detected in Mexico City.

METHODS

We analyzed data from the National Epidemiological Surveillance System in the Greater Mexico City area, an open-source dataset comprising daily updated cases tested using realtime RT-PCR to confirm SARS-CoV-2 using nasopharyngeal swabs according to the Berlin Protocol [8]. RS included fever, dyspnea, cough, polypnea or cyanosis at initial evaluation, whilst non-RS (NRS) included headache, myalgias, arthralgias, general malaise, abdominal pain, chest pain, conjunctivitis, irritability or vomiting. We defined cases with RS+NRS with ≥1 RS and any or none NRS. Cases with NRS had ≥1 NRS without RS, whilst asymptomatic cases had no symptoms. Pre-symptomatic cases were initially asymptomatic but eventually required hospital admission after follow-up. To contrast previous definitions symptomatic/asymptomatic cases based only on RS, we combined asymptomatic and NRS cases and referred to them as cases without RS (WoRS); we confirmed these definitions using correspondence analyses to cluster symptoms with comparable similarity (Supplementary Material). NRS and asymptomatic cases were assessed outside the established framework for suspected COVID-19 cases in Mexico by convenience sampling and contact tracing. We also estimated 7-day rolling average positivity rates (PR) for RS+NRS, NRS and asymptomatic/presymptomatic cases. Follow-up was conducted for all non-hospitalized cases up to 14 days; outcomes for all patients included hospital discharge due to clinical improvement or voluntary, ambulatory/treatment follow-up or death. Severe COVID-19 was defined as a composite of death, ICU admission and intubation. Complete description of statistical analyses and available variables are detailed in Supplementary Material.

RESULTS

71

72

73

74

75

76

77

78

79

80

81

82

- Study population
- As of 23rd July 2020, a total of 212,708 subjects were tested for SARS-CoV-2 in Mexico City.
- 84 From 80,735 cases with confirmed SARS-CoV-2 infection (Positivity rate 49.0%), 9,659 cases
- were WoRS (12.0%). Overall, 23,992 NRS cases had been evaluated, amongst whom 5,605
- had confirmed SARS-CoV-2 infection (Overall Positivity rate: 26.5%); similarly, 21,628 initially
- 87 asymptomatic cases were evaluated and 4,054 cases had confirmed SARS-CoV-2 infection
- 88 (Positivity rate: 21.4%). Notably, 7-day PRs had been steadily decreasing for all patient
- 89 categories (Supplementary Material). NRS cases were younger, predominantly female and,
- 90 interestingly, had lower prevalence of NRS compared to cases with RS+NRS. Initially
 - asymptomatic cases were younger compared to RS+NRS cases, with similar trends for lower
- 92 rates of comorbidities compared to both RS+NRS and NRS cases (Figure 1, Table 1).
- 93 Profiling NRS cases with SARS-CoV-2 infection
- 94 Amongst NRS cases (n=5,605), 283 subjects were hospitalized (5.0%), 26 required mechanical
- 95 ventilatory support (MVS) (0.5%), 27 required intensive care unit (ICU) admission (0.5%).
- Overall, 96 patients died (1.7%), of whom 22 were ambulatory and 74 hospitalized. Predictors

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

increased risk for severe COVID-19 in NRS cases included vomiting, diabetes, and hypertension; decreased risk of severe COVID-19 was associated with rhinorrhea, previous exposure to suspected viral cases and healthcare workers. Independent predictors of mortality in NRS included older age, diabetes, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD) and decreased risk associated with previous exposure to suspected viral cases (Supplementary Material). After follow-up, 481 patients were still under domiciliary surveillance, 109 remained hospitalized, 97 were discharged after recovery, 3 had voluntary discharge and 4,819 had completed follow-up with domiciliary surveillance without developing RS (86.0%). Profiling pre-symptomatic/asymptomatic cases with SARS-CoV-2 infection Amongst initially asymptomatic patients (n=4,054), 139 were hospitalized (3.4%), 9 required MVS (0.2%) and 29 required ICU admission (0.7%). We recorded 24 deaths (0.6%) amongst whom 8 were ambulatory and 16 were hospitalized (Table 1). Predictors for severe COVID-19 included younger age, cardiovascular disease, CKD, diabetes and a reduced risk associated to known previous exposure to suspected viral cases; predictors of lethality included older age and CKD. Currently, 444 patients were still under domiciliary surveillance, 84 remained hospitalized, 38 were discharged after recovery, 1 had a voluntary discharge, and 3,463 had completed follow-up without developing symptoms (85.4%). Predictors and outcomes for RS+NRS, NRS and asymptomatic cases Compared to asymptomatic, NRS cases were associated with younger age, reduced previous viral exposure, healthcare workers, diabetes, obesity, female sex, hypertension and smoking. Similarly, compared to WoRS, RS+NRS cases were associated with asthma, COPD, older age, male sex, diabetes, obesity, hypertension, reduced previous viral exposure (Figure 2). Compared to pre-symptomatic/asymptomatic cases, risk of severe COVID-19 was not significantly higher for NRS, but it was for RS+NRS (HR 3.91, 95%CI 2.95-5.18), adjusted for age, sex and comorbidities. However, NRS and RS+NRS had higher mortality compared to

asymptomatic cases (Breslow-Cox p<0.001, **Figure 2**); adjusting for age, sex and comorbidities, NRS (HR 2.32, 95%CI 1.48-3.63) or RS+NRS cases (HR 6.22, 95%CI 4.17-9.29) retained higher mortality compared to asymptomatic cases.

DISCUSSION

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

Here, we present a comprehensive report of pre-symptomatic/asymptomatic COVID-19 cases in Mexico City. We show that the definition of asymptomatic SARS-CoV-2 infection should be extended beyond RS to identify subjects at lowest risk of subsequent complications for domiciliary treatment who might contribute to further SARS-CoV-2 spread. We also report a low prevalence of pre-symptomatic cases amongst those who were initially classified as asymptomatic but eventually were hospitalized or had outcomes related to severe COVID-19 [9]. This data confirms observations from other populations and highlights the relevance of identifying pre-symptomatic/asymptomatic cases, given conflicting evidence on viral shedding for pre-symptomatic/asymptomatic cases, and data suggesting evidence of subclinical lung abnormalities which must be assessed longitudinally to rule out long-term impacts of SARS-CoV-2 infection [10]. Notably, a consistent predictor of outcomes for NRS cases and presymptomatic/asymptomatic cases are previous exposure to suspected viral cases, highlighting the relevance of contact tracing and prompt case identification. Studies assessing natural history of asymptomatic SARS-CoV-2 infections highlighted the role of age and comorbidity in the subsequent development of symptoms, which is consistent with our observations [11]. Domiciliary surveillance in Mexico City focused on outcomes but not individual symptom onset, which might limit our ability to identify all pre-symptomatic cases, particularly those who only develop mild symptoms. Regardless, only a small fraction of presymptomatic cases developed severe COVID-19 after being initially determined as asymptomatic, most of whom had underlying cardio-metabolic comorbidities or were susceptible for complications of COVID-19 attributable to unmasked cardiometabolic comorbidities. Asymptomatic SARS-CoV-2 infections have been postulated to elicit lower

immune responses and diminished antibody production compared to symptomatic cases. Severe COVID-19 in pre-symptomatic cases might be attributable to a combination of decreased early immune response to SARS-CoV-2 infection and late enhanced pro-inflammatory responses in subjects with comorbidities [10,12]. This might also extend to subjects with NRS with COVID-19 whom have previously been reported to delay seeking medical attention and have prolonged viral shedding compared with subjects with RS [13]. Here, we assessed a thorough constellation of symptoms in one of the largest studies of pre-symptomatic/asymptomatic SARS-CoV-2 infections. Limitations include non-assessment of atypical SARS-CoV-2 symptoms which might occur amongst otherwise asymptomatic cases, particularly in older adults [14], and the lack of systematized sampling, which does not allow for an accurate estimation for the rates of asymptomatic cases in Mexico City. Our results highlight the need to systematize definition of asymptomatic cases and extend testing by contact tracing to detect asymptomatic SARS-CoV-2 infections as one of the mitigations strategies to reduce transmission of SARS-CoV-2 in Mexico City and Mexico in general [15].

ACKNOWLEDGMENTS

NEAV, JPBL, and AVV are enrolled at the PECEM program of the Faculty of Medicine at UNAM. JPBL and AVV are supported by CONACyT. The authors would like to acknowledge the invaluable work of all of Mexico's healthcare community in managing the COVID-19 epidemic. Its participation in the COVID-19 surveillance program has made this work a reality, we are thankful for your effort.

DATA AVAILABILITY

171 All data sources and R code are available for reproducibility of results at

https://github.com/oyaxbell/covid asymptomatic cdmx.

AUTHOR CONTRIBUTIONS

Research idea and study design OYBC, NEAV, AVV, JPBL, CAFM, AMS; data acquisition: OYBC; data analysis/interpretation: OYBC, JPBL, NEAV, AVV, CAFM, AMS; statistical analysis: OYBC; manuscript drafting: OYBC, NEAV, AVV, JPBL, CAFM, AMS; supervision or mentorship: OYBC. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions about the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

FUNDING: No funding was received.

182 CONFLICT OF INTEREST/FINANCIAL DISCLOSURE: Nothing to disclose.

REFERENCES

- 185 1. Buitrago-Garcia DC, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Salanti G, et al.
- The role of asymptomatic SARS-CoV-2 infections: rapid living systematic review and
- meta-analysis. medRxiv. 2020; doi:10.1101/2020.04.25.20079103
- 188 2. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative
- 189 Review. Ann Intern Med. 2020; doi:10.7326/M20-3012
- 190 3. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al.
- 191 Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility.
- N Engl J Med. 2020;382: 2081–2090. doi:10.1056/NEJMoa2008457
- 193 4. Sakurai A, Sasaki T, Kato S, Hayashi M, Tsuzuki S-I, Ishihara T, et al. Natural History of
- 194 Asymptomatic SARS-CoV-2 Infection. N Engl J Med. 2020;
- 195 doi:10.1056/NEJMc2013020
- 196 5. Imperial College COVID-19 Response Team, Lavezzo E, Franchin E, Ciavarella C,
- 197 Cuomo-Dannenburg G, Barzon L, et al. Suppression of a SARS-CoV-2 outbreak in the
- 198 Italian municipality of Vo. Nature. 2020; doi:10.1038/s41586-020-2488-1
- 199 6. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas-Vázquez A, González-
- 200 Díaz A, Márquez-Salinas A, et al. Predicting mortality due to SARS-CoV-2: A
- 201 mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico. J
- 202 Clin Endocrinol Metab. 2020; doi:10.1210/clinem/dgaa346
- 203 7. Huff HV, Singh A. Asymptomatic transmission during the COVID-19 pandemic and
- implications for public health strategies. Clin Infect Dis. 2020; doi:10.1093/cid/ciaa654
- 205 8. Covid-19 SINAVE Ciudad de México Datos CDMX [Internet]. [cited 28 Jun 2020].
- 206 Available: https://datos.cdmx.gob.mx/explore/dataset/base-covid-sinave/table/
- 9. Meng H, Xiong R, He R, Lin W, Hao B, Zhang L, et al. CT imaging and clinical course of
- asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China. J Infect.
- 209 2020;81: e33–e39. doi:10.1016/j.jinf.2020.04.004

210 Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng H-J, Yuan J, et al. Clinical and immunological 10. assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020; 211 212 doi:10.1038/s41591-020-0965-6 213 [2006.08471] Probability of symptoms and critical disease after SARS-CoV-2 infection 214 [Internet]. [cited 28 Jun 2020]. Available: https://arxiv.org/abs/2006.08471 215 12. Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen M-C, et al. 216 Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in 217 COVID-19. Allergy. 2020; doi:10.1111/all.14364 Han C, Duan C, Zhang S, Spiegel B, Shi H, Wang W, et al. Digestive Symptoms in 218 13. 219 COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA 220 Testing, and Outcomes. Am J Gastroenterol. 2020;115: 916–923. 221 doi:10.14309/ajg.0000000000000664 Varatharaj A, Thomas N, Ellul MA, Davies NWS, Pollak TA, Tenorio EL, et al. 222 14. 223 Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-224 wide surveillance study. The Lancet Psychiatry. 2020; doi:10.1016/S2215-225 0366(20)30287-X Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles' Heel of 226 Current Strategies to Control Covid-19. N Engl J Med. 2020;382: 2158–2160. 227 doi:10.1056/NEJMe2009758 228

Table 1. Descriptive characteristics of symptomatic and asymptomatic SARS-CoV-2 cases in Mexico City. *Abbreviations*: COPD: Chronic obstructive pulmonary disease; HIV/AIDS: Human immunodeficiency virus and/or acquired immunodeficiency syndrome; CKD: Chronic kidney disease, CDV: Cardiovascular disease; HCW: Healthcare worker

Parameter	RS+NRS (n=71,076)	NRS (n=5,605)	Pre-asymptomatic/	
			Asymptomatic	P-value
			(n=4,054)	
Male sex (%)	38125 (53.6)	2427 (43.3)	2135 (52.7)	<0.001
Age (years)	45.92±16.37	40.94±15.75	40.94±17.86	<0.001
Mortality (%)	8556 (12.0)	96 (1.7)	24 (0.6)	<0.001
Hospitalizacion (%)	19439 (27.3)	283 (5.0)	139 (3.4)	<0.001
ICU admission (%)	1668 (2.3)	27 (0.5)	29 (0.7)	<0.001
Mechanical-Ventilation (%)	2809 (4.0)	26 (0.5)	9 (0.2)	<0.001
Severe COVID-19 (%)	9565 (13.5)	111 (2.0)	49 (1.2)	<0.001
Previous viral exposure (%)	28304 (39.8)	3189 (56.9)	2387 (58.7)	<0.001
Diabetes (%)	10903 (15.3)	506 (9.0)	243 (6.0)	<0.001

COPD (%)	1131 (1.6)	33 (0.6)	21 (0.5)	<0.001
Asthma (%)	1694 (2.4)	107 (1.9)	46 (1.1)	<0.001
HIV/AIDS (%)	322 (0.5)	19 (0.3)	7 (0.2)	0.016
Obesity (%)	14185 (20.0)	809 (14.4)	312 (7.7)	<0.001
Smoking status (%)	7521 (10.6)	616 (11.0)	272 (6.7)	<0.001
CVD (%)	1680 (2.4)	92 (1.6)	40 (1.0)	<0.001
Hypertension (%)	13078 (18.4)	632 (11.3)	303 (7.47)	<0.001
Immunosupression (%)	1092 (1.5)	53 (0.9)	42 (1.0)	<0.001
CKD (%)	1321 (1.9)	50 (0.9)	28 (0.7)	<0.001
Healthcare worker (%)	11532 (16.2)	1115 (19.9)	443 (10.9)	<0.001

FIGURE LEGENDS




FIGURE 1. Histogram comparing case distribution according to age groups comparing cases with RS+NRS, NRS and asymptomatic SARS-CoV-2 infection, demonstrating the role of age in determining asymptomatic SARS-CoV-2 infections (A). We also show a comparison of the distribution of NRS related to SARS-CoV-2 infections in subjects with RS+NRS and NRS only.

<u>Abbreviations</u>: RS: Respiratory symptoms; NRS: Non-respiratory Symptoms; Sudden onset: Patient report of sudden onset of symptomatology.




FIGURE 2. Factors associated with presence of RS+NRS compared to WoRS (NRS + Asymptomatic), and NRS compared to asymptomatic cases (NRS) with SARS-CoV-2 infection (A). We also show the and comparison of 30-day mortality rates between RS+NRS cases, NRS and asymptomatic SARS-CoV-2 infections in Mexico City.

<u>Abbreviations</u>: RS: Respiratory symptoms; NRS: Non-respiratory Symptoms; COPD: Chronic obstructive pulmonary disease; CKD: Chronic kidney disease; HCW: Health-care workers; Previous viral exposure: Prior contact with a patient with suspected viral infection.